Companies Dominating the Scleroderma Therapeutics Landscape
- Sanofi
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- Certa Therapeutics
- Pfizer Inc.
- Teva Pharmaceuticals
- Boehringer Ingelheim International
- Bristol-Myers Squibb Company
- Biogen
- F. Hoffman La-Roche Ltd.
- Bayer AG
- Galderma Laboratories
- Aisa Pharmaceuticals
The global scleroderma therapeutics market is positioned for a profitable growth curve during the forecast period. Key market players in the sector are investing in clinical trials for new therapeutics for scleroderma treatment, and in acquisitions to improve distribution channels in emerging markets.
Here are some key players in the market:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
2025 Scleroderma Therapeutics Market is estimated at USD 2.74 billion.
The global scleroderma therapeutics market size crossed USD 2.6 billion in 2024 and it is set to experience impressive growth, with a CAGR above 6.9%, to exceed USD 6.19 billion by 2037.
North America is estimated to collect USD 2.76 billion by 2037, attributed to rising diagnosis and a supportive regulatory ecosystem.
The oral segment via route of administration in the global scleroderma registered the largest revenue share of 69.8% in 2024. The segment’s growth is attributed to the increasing adoption of treatment due to convenience.
